Psoriasis has a profound impact on patients’ well-being and is often linked to various psychiatric comorbidities, including depression, anxiety, and suicidality.1 Adding to this impact is the increased prevalence of comorbidities such as obesity, hypertension, dyslipidemia, diabetes, nonalcoholic fatty liver disease, smoking, and metabolic syndrome when compared to the general population.2-6 Fortunately, many treatment options exist for patients with psoriasis, with more options in development utilizing novel pathways. New findings continue to emerge that affect the way that we view the disease process, the risk of serious complications, and the possibilities for new drug development. As the understanding and treatment of psoriasis has changed significantly in recent years, it is critical that clinicians who manage this disease have a thorough understanding of the disease and treatment options.
The goal of this educational activity is to provide Physician Assistants (PAs) and other healthcare professionals who treat psoriasis patients with an understanding of the inflammatory targets for current and emerging biologic agents, the impact of complicating comorbidities, and the importance of patient quality of life in treatment decisions. This activity will give participants the ability to not only increase the number of psoriasis patients who achieve treatment goals but also to improve their overall health and quality of life.
1. Kurd SK, et al. Arch Dermatol. 2010.
2. Neimann AL, et al. J Am Acad Dermatol. 2006.
3. Cohen AD, et al. Dermatology. 2008.
4. Gisondi P, et al. Am J Cardiol. 2010.
5. Gisondi P, et al. J Hepatol. 2009.
6. Prey S, et al. J Eur Acad Dermatol Venereol. 2010.